Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **intracellular calcium signaling pathway in vascular smooth muscle** governs fundamental processes involved in regulating vascular tone, contractility, and blood pressure[1][2][5][6]. In vascular smooth muscle cells (VSMCs), an increase in intracellular Ca²⁺ concentration is typically mediated by: - **Calcium influx** through plasma membrane ion channels, especially L-type voltage-dependent calcium channels (VDCCs), as well as T-type and various transient receptor potential (TRP) channels[1][2][5][6]. - **Release of Ca²⁺** from intracellular stores, such as the sarcoplasmic reticulum, via ryanodine receptors (RyR) and inositol 1,4,5-trisphosphate receptors (IP₃R)[1][2][4][5][6]. Activation of this pathway often begins with G-protein-coupled receptors (GPCRs) responding to physiological stimuli, which leads to the production of secondary messengers (e.g., IP₃), triggering intracellular Ca²⁺ release from stores or promoting Ca²⁺ entry from the extracellular space[3][5]. Elevated Ca²⁺ binds to calmodulin, activating myosin light chain kinase (MLCK), which phosphorylates myosin, enabling actin-myosin interaction and smooth muscle contraction[5][6]. This pathway also affects elastic and adhesive functions of VSMCs by modulating cytoskeletal proteins and integrin-mediated interactions with the extracellular matrix[2]. Relaxation is mediated by mechanisms that decrease cytosolic Ca²⁺, including SERCA pumps, mitochondrial Ca²⁺ uniporters, sodium-calcium exchangers, and plasma membrane Ca²⁺-ATPases[5]. **Note:** This entry is not a single molecule, protein, or classical target such as a "receptor," "enzyme," or "ion channel," but rather a broad cellular pathway involving multiple molecular components (e.g., channels, receptors, kinases)[1][4][5]. Therefore, it should not be considered a single therapeutic target, but many core proteins within this pathway (such as L-type calcium channels, ryanodine receptors) are individually considered drug targets.
Calcium channel blockade (reduces calcium influx through voltage-gated channels) - Modulation of intracellular calcium release (inhibition or activation of ryanodine or IP₃ receptors) - Inhibition of contractile apparatus activation
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intracellular calcium signaling pathway in vascular smooth muscle.